Published in Mayo Clin Proc on February 01, 2010
Coronary Revascularization in Patients with CKD Stage 5D: Pragmatic Considerations. J Am Soc Nephrol (2016) 0.75
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis. Clin J Am Soc Nephrol (2017) 0.75
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med (2004) 49.19
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA (2005) 9.81
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med (2001) 6.38
Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med (2002) 3.71
Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol (2006) 3.45
Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation (2006) 3.08
Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol (2003) 2.99
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ (2008) 2.98
Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol (2005) 2.42
Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA (2006) 2.22
Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation (2007) 2.15
Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol (2008) 2.11
Platelet dysfunction and end-stage renal disease. Semin Dial (2006) 2.09
Short- and long-term clinical outcomes of coronary drug-eluting stent recipients presenting with chronic renal disease. J Invasive Cardiol (2007) 2.05
The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol (2002) 2.03
Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol (2005) 1.99
Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J (2003) 1.92
Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation (2002) 1.91
Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation (2002) 1.88
Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Circulation (2006) 1.80
Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation (2004) 1.72
Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. J Invasive Cardiol (2006) 1.61
Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation. Int J Cardiol (2007) 1.56
Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation (2003) 1.38
Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant (2006) 1.17
Chronic kidney disease is associated with angiographic coronary artery disease. Am J Nephrol (2007) 1.15
Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure. Catheter Cardiovasc Interv (2002) 1.12
Sirolimus-eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. Circ J (2008) 1.04
Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol (2007) 1.03
Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation (2000) 1.02
The renal patient with coronary artery disease: current concepts and dilemmas. J Am Coll Cardiol (2004) 1.02
Impact of drug-eluting stents on clinical and angiographic outcomes in dialysis patients. Circ J (2007) 1.01
Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial. Am Heart J (2005) 1.01
Impact of moderate or severe renal insufficiency on long-term outcomes in patients undergoing drug-eluting stent based coronary intervention. Int J Cardiol (2008) 0.95
Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients. J Invasive Cardiol (2006) 0.95
Coronary revascularization in diabetic chronic kidney disease/end-stage renal disease: a nephrologist's perspective. Clin J Am Soc Nephrol (2006) 0.92
Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. Am Heart J (2006) 0.92
Long term clinical outcomes in patients with moderate renal insufficiency undergoing stent based percutaneous coronary intervention. Chin Med J (Engl) (2006) 0.92
Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost (1996) 0.90
Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol (1994) 0.89
Images in cardiovascular medicine. Damage to polymer of a sirolimus-eluting stent. Circulation (2006) 0.88
Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force. Catheter Cardiovasc Interv (2007) 0.88
Morbidity, mortality and economic burden of renal impairment in cardiac intensive care. Intern Med J (2006) 0.87
Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial. J Am Coll Cardiol (2004) 0.86
Impact of chronic renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary intervention with sirolimus-eluting stents versus bare metal stents. Am J Cardiol (2006) 0.86
The association between kidney function, coronary artery disease, and clinical outcome in patients undergoing coronary angiography. J Korean Med Sci (2009) 0.86
Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents. Catheter Cardiovasc Interv (2007) 0.85
Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. Am J Cardiol (2005) 0.85
Impact of impaired renal function and diabetes on long-term prognosis in patients undergoing primary angioplasty for acute coronary syndrome. Intern Med (2008) 0.85
Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol (2005) 0.84
Phospholipase A2 activity in platelets of patients with uremia. Platelets (2002) 0.82
Impact of renal insufficiency on angiographic, procedural, and in-hospital outcomes following percutaneous coronary intervention. Am J Cardiol (2008) 0.81
Clinical outcomes after percutaneous coronary intervention with drug-eluting stents in dialysis patients. J Invasive Cardiol (2006) 0.80
Comparison of long-term clinical outcome after sirolimus-eluting stent implantation in patients with and without hemodialysis. Int Heart J (2007) 0.80
Cytokine production during hemodialysis: effects of dialytic membrane and complement activation. Am J Nephrol (1996) 0.80
Rates of stent thrombosis in bare-metal versus drug-eluting stents (from a large Australian multicenter registry). Am J Cardiol (2008) 0.80
Percutaneous coronary intervention in patients with end-stage renal disease. Kidney Blood Press Res (2006) 0.80
Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). Am J Cardiol (2003) 0.79
Treatment of coronary artery disease in dialysis patients with sirolimus-eluting stents: 1-year clinical follow-up of a consecutive series of cases. J Invasive Cardiol (2004) 0.79
[Limitation on efficacy of sirolimus-eluting stent implantation in patients on hemodialysis]. J Cardiol (2007) 0.76
Granulocyte activation in restenosis after percutaneous transluminal coronary angioplasty. Jpn Circ J (1996) 0.76
Long-term outcome after percutaneous transluminal coronary angioplasty in patients with chronic renal failure with and without diabetic nephropathy. Nephron (2001) 0.76
Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol (2002) 0.76
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med (2009) 17.17
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation (2002) 4.99
Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol (2004) 4.62
2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2014) 4.57
Drug-eluting coronary-artery stents. N Engl J Med (2013) 3.69
Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol (2011) 3.66
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J (2011) 3.29
Incidence, retrieval methods, and outcomes of stent loss during percutaneous coronary intervention: a large single-center experience. Catheter Cardiovasc Interv (2005) 3.20
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16
Acute coronary syndrome and khat herbal amphetamine use: an observational report. Circulation (2011) 3.11
Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol (2007) 2.88
Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation (2003) 2.81
Transcatheter aortic valve implantation: assessing the learning curve. JACC Cardiovasc Interv (2011) 2.63
Myocardial bridging. Eur Heart J (2005) 2.56
Trends in cause of death after percutaneous coronary intervention. Circulation (2014) 2.52
Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol (2003) 2.52
Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003. J Am Coll Cardiol (2005) 2.51
Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. JACC Cardiovasc Interv (2010) 2.51
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol (2007) 2.47
Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation (2007) 2.47
2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol (2012) 2.44
Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation (2008) 2.42
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J (2004) 2.42
Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke. JAMA (2004) 2.32
Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation (2007) 2.31
2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2014) 2.30
Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation (2006) 2.29
Chronic total occlusion angioplasty in the United States. JACC Cardiovasc Interv (2009) 2.24
Intravascular ultrasound-guided treatment for angiographically indeterminate left main coronary artery disease: a long-term follow-up study. J Am Coll Cardiol (2005) 2.21
Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS). Circulation (2003) 2.21
Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag (2005) 2.15
Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents. Mayo Clin Proc (2004) 2.11
Volume-outcome relationships for percutaneous coronary interventions in the stent era. Circulation (2005) 2.03
The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol (2002) 2.03
Low-output, low-gradient aortic stenosis in patients with depressed left ventricular systolic function: the clinical utility of the dobutamine challenge in the catheterization laboratory. Circulation (2002) 2.00
Rheolytic thrombectomy with Angiojet in thrombus-containing lesions. Catheter Cardiovasc Interv (2002) 1.98
The history of the German Cardiac Society and the American College of Cardiology and their two founders. J Am Coll Cardiol (2013) 1.97
Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol (2007) 1.91
Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol (2006) 1.90
Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation (2002) 1.88
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation (2004) 1.87
Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). Circulation (2012) 1.87
Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol (2009) 1.87
A risk score to predict in-hospital mortality for percutaneous coronary interventions. J Am Coll Cardiol (2006) 1.84
Clinical determinants of radiation dose in percutaneous coronary interventional procedures: influence of patient size, procedure complexity, and performing physician. JACC Cardiovasc Interv (2011) 1.80
Mortality differences between men and women after percutaneous coronary interventions. A 25-year, single-center experience. J Am Coll Cardiol (2008) 1.78
Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation (2012) 1.77
Comparison of coronary artery stenting outcomes in the eras before and after the introduction of drug-eluting stents. Circulation (2008) 1.77
Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data. Eur J Cardiothorac Surg (2011) 1.77
Long-term outcomes of fractional flow reserve-guided vs. angiography-guided percutaneous coronary intervention in contemporary practice. Eur Heart J (2013) 1.76
Incidental renal artery stenosis among a prospective cohort of hypertensive patients undergoing coronary angiography. Mayo Clin Proc (2002) 1.74
Validation of Mayo Clinic risk adjustment model for in-hospital complications after percutaneous coronary interventions, using the National Heart, Lung, and Blood Institute dynamic registry. J Am Coll Cardiol (2003) 1.74
Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. JACC Cardiovasc Interv (2010) 1.74
Coronary stent restenosis in patients treated with cilostazol. Circulation (2005) 1.73
Factors associated with 30-day readmission rates after percutaneous coronary intervention. Arch Intern Med (2011) 1.70
Management and outcomes of Middle Eastern patients admitted with acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE). Acta Cardiol (2009) 1.70
Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. J Am Coll Cardiol (2007) 1.68
Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension (2008) 1.67
Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv (2011) 1.66
The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. Am Heart J (2006) 1.65
Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina. Eur Heart J (2006) 1.63
Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol (2002) 1.62
Myocardial bridging in adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2003) 1.62
Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. Am Heart J (2004) 1.60
Long-term mortality of coronary artery bypass grafting and bare-metal stenting. Ann Thorac Surg (2011) 1.60
30-day readmission for patients undergoing percutaneous coronary interventions in New York state. JACC Cardiovasc Interv (2011) 1.59
Enhanced external counterpulsation for ischemic heart disease: what's behind the curtain? J Am Coll Cardiol (2003) 1.59
Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation (2002) 1.57
Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv (2011) 1.56
The truth and consequences of the COURAGE trial. J Am Coll Cardiol (2007) 1.55
Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. Circulation (2004) 1.54
Sex differences in atheroma burden and endothelial function in patients with early coronary atherosclerosis. Eur Heart J (2008) 1.53
Heart failure in patients hospitalized with acute coronary syndromes: observations from the Gulf Registry of Acute Coronary Events (Gulf RACE). Eur J Heart Fail (2009) 1.53
Medical device innovation: prospective solutions for an ecosystem in crisis. Adding a professional society perspective. JACC Cardiovasc Interv (2012) 1.53
Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York. Circulation (2012) 1.52
Percutaneous coronary intervention at centers with and without on-site surgery: a meta-analysis. JAMA (2011) 1.51
Remote ischemic preconditioning immediately before percutaneous coronary intervention does not impact myocardial necrosis, inflammatory response, and circulating endothelial progenitor cell counts: a single center randomized sham controlled trial. Catheter Cardiovasc Interv (2012) 1.51
Staged versus one-time complete revascularization with percutaneous coronary intervention for multivessel coronary artery disease patients without ST-elevation myocardial infarction. Circ Cardiovasc Interv (2013) 1.51
Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation (2004) 1.51
Turf wars and silos-joined at the hip: what can be done? Catheter Cardiovasc Interv (2007) 1.50
Low-risk percutaneous coronary interventions without on-site cardiac surgery: two years' observational experience and follow-up. Am Heart J (2003) 1.50
Location of femoral artery access and correlation with vascular complications. Catheter Cardiovasc Interv (2011) 1.50
Clinical practice. Hypertrophic obstructive cardiomyopathy. N Engl J Med (2004) 1.50
Transcatheter valve therapy: a professional society overview from the American College of Cardiology Foundation and the Society of Thoracic Surgeons. Ann Thorac Surg (2011) 1.49
Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv (2008) 1.49
Association of door-in to door-out time with reperfusion delays and outcomes among patients transferred for primary percutaneous coronary intervention. JAMA (2011) 1.48
Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv (2004) 1.48
Annual Outcomes With Transcatheter Valve Therapy: From the STS/ACC TVT Registry. Ann Thorac Surg (2016) 1.48